Pharmaceutical cleanroom HVAC

In pharmaceutical manufacturing, the HVAC system is part of the quality system. It protects products from contamination, protects workers and the environment from potent materials, and maintains the conditions that keep products stable. Regulators treat HVAC as a GMP-critical utility, which means it must be designed for its intended purpose, qualified, monitored and controlled through change management.

In Canada, drug manufacturers are licensed by Health Canada and must follow its Good Manufacturing Practices guide for drug products. Health Canada is a member of PIC/S, and its approach to sterile manufacturing aligns with PIC/S and EU GMP Annex 1. This guide outlines how these requirements translate into HVAC design. It is general guidance; each facility's quality unit and regulatory advisers determine the specific requirements.

Start with a contamination control strategy

The 2022 revision of Annex 1 made the contamination control strategy (CCS) central for sterile manufacturing. A CCS is a documented, facility-wide plan that identifies contamination risks and the controls that address them. HVAC contributes several controls:

• Filtration of supply air.
• Airflow patterns that protect exposed product.
• Pressure cascades that keep contamination moving in the right direction.
• Segregation of areas and products.
• Temperature and humidity control.
• Monitoring that detects loss of control.

Even for non-sterile facilities, a documented risk assessment, often following ICH Q9 quality risk management principles, should drive HVAC design choices.

Sterile manufacturing

Sterile products, such as injectables and ophthalmic products, use GMP Grades A to D. Grade A zones, where product is exposed, use unidirectional airflow from HEPA filters, typically within isolators or restricted access barrier systems (RABS). Background rooms use non-unidirectional airflow. See GMP cleanroom grades A to D for particle and microbial limits.

Key HVAC features for sterile facilities:

• Terminal HEPA filtration for all classified rooms, typically H13 or H14, leak tested after installation and at requalification.
• Pressure differentials of about 10 Pa between grades, with airlocks for personnel and materials.
• Continuous monitoring of particles in Grade A and of pressures in classified areas, with alarms.
• Airflow visualization demonstrating protection of critical zones under dynamic conditions.
• Separate gowning airlocks for entry and, where justified, exit.

Isolators vs RABS

Isolators are sealed enclosures with their own HEPA-filtered air supply, often decontaminated with vaporized hydrogen peroxide. Because the isolator provides separation, the surrounding room can usually be Grade C or D rather than Grade B. That significantly reduces the size of the most demanding HVAC areas and the gowning burden. Isolator exhaust and decontamination cycles must be integrated with the room HVAC, including any aeration exhaust.

RABS provide a physical barrier but are opened in some circumstances, so they typically require a Grade B background.

Non-sterile manufacturing

Oral solid dosage (tablets and capsules), liquids, creams and other non-sterile products do not use Annex 1 grades, but they still require controlled environments. The main HVAC concerns are:

• Cross-contamination. Dust from one product must not reach another. This is especially important in multi-product facilities and where potent compounds are handled.
• Containment of potent compounds. Operator protection may require negative pressure process rooms, local exhaust, containment equipment and dedicated exhaust with HEPA filtration.
• Humidity control for moisture-sensitive products.
• Dust control from processes such as granulation, milling, blending and compression.

Many non-sterile facilities define cleanliness levels referencing ISO 8 or Grade D at rest, though this is a manufacturer's choice based on risk.

Recirculation vs once-through air

Recirculating air saves large amounts of energy but can carry dust from one room to another. Options include:

1. Recirculating only within a single room or suite handling one product.
2. Recirculating with HEPA filtration in the return to remove dust before air is reused.
3. Using once-through (100 percent outdoor air) systems for highly potent or high-risk products.

The choice should be justified in the risk assessment. Once-through systems in Canadian climates carry a heavy heating and humidification burden in winter, so heat recovery that does not risk cross-contamination, such as runaround coil loops, is often used.

Pressure regimes for potent products

When a product is both sensitive and hazardous, the pressure regime must protect both product and people. Options include:

• Negative process room with positive airlock (bubble). The airlock is higher than both corridor and process room, stopping dust from leaving and corridor air from entering.
• Positive process room with negative airlock (sink). Air flows into the airlock from both sides and is exhausted.
• Negative process room in a negative suite. For high containment, with operator protection by equipment.

These arrangements are described in cleanroom pressurization cascades.

Temperature and humidity

GMP does not prescribe numbers; conditions come from product stability data and operator comfort. Typical ranges are about 18 to 22 C and 30 to 60 percent RH, with lower humidity for moisture-sensitive products. Clean steam or high-purity water should be used for humidification, avoiding boiler treatment chemicals. See temperature and humidity control in cleanrooms.

Qualification

Pharmaceutical HVAC systems are qualified, typically in stages:

Commissioning following good engineering practice supports qualification, and many projects integrate the two so that commissioning tests can be leveraged for IQ and OQ. ISPE guidance documents are widely used for this.

Monitoring and change control

After qualification, the system is kept in a state of control:

• Continuous monitoring of critical parameters with alarms and data integrity controls.
• Environmental monitoring for particles and microorganisms per the monitoring program.
• Periodic requalification, at least every six months for Grade A and B and every 12 months for Grade C and D under Annex 1.
• Formal change control for any modification to HVAC equipment, setpoints or controls.
• Preventive maintenance with documented procedures, including filter changes and sensor calibration.

Building automation systems that control GMP parameters may need computer system validation. Many facilities separate GMP monitoring into an independent, validated system and leave the building automation system as non-GMP control.

Key takeaways

• Pharmaceutical HVAC is a GMP-critical utility that must be designed, qualified, monitored and controlled under change management.
• A contamination control strategy and risk assessment should drive design choices.
• Sterile facilities follow Annex 1 Grades A to D; isolators can reduce background room demands substantially.
• Non-sterile facilities focus on cross-contamination, potent compound containment, dust and humidity.
• Qualification (DQ, IQ, OQ, PQ) and periodic requalification demonstrate continued performance.